$ANIK News

B. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

Anika Therapeutics, Inc. (ANIK) Q2 2026 Earnings Call Transcript

Anika Therapeutics (NASDAQ:ANIK) Soars on Q2 Earnings Beat, Revenue and EPS Top Estimates

Anika Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

Anika Therapeutics Raises FY2026 Sales Guidance from $114.000M-$122.500M to $118.460M-$124.101M vs $118.612M Est

Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

President of Anika Therapeutics Picks Up 51% More Stock

Bullish On Anika Therapeutics's Pullback As Integrity Scales

Anika Therapeutics, Inc. Q1 2026 Earnings Call Summary

Anika Therapeutics Q1 Earnings Call Highlights

Anika Therapeutics Inc (NASDAQ:ANIK) Soars on Q1 Earnings and Revenue Beat

Anika Therapeutics, Inc. (ANIK) Q1 2026 Earnings Call Transcript

Anika Reports First Quarter 2026 Financial Results

Anika Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Anika Therapeutics Affirms FY2026 Sales Guidance of $114.000M-$122.500M vs $117.220M Est

Anika Therapeutics Q1 Adj. EPS $0.27 Beats $(0.16) Estimate, Sales $29.612M Beat $28.142M Estimate

Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Top 2 Health Care Stocks That May Crash This Quarter